Different therapeutic effects of distinct KISS1 fragments on breast cancer in vitro and in vivo

Song,Guo-Qing; Zhao,Yi

doi:10.3892/ijo.2013.2029

Different therapeutic effects of distinct KISS1 fragments on breast cancer in vitro and in vivo

Authors:
- Guo-Qing Song
- Yi Zhao
View Affiliations

Affiliations: Department of Pancreatic and Breast Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: July 23, 2013 https://doi.org/10.3892/ijo.2013.2029
Pages: 1219-1227

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most frequently diagnosed cancer in women. In these studies, a metastasis suppressor gene, KISS1 and its truncated fragment, were overexpressed in the breast cancer cell line MDA-MB-231. In addition, KISS1 expression was downregulated in MDA-MB-157 cell line using a KISS1-specific siRNA. The effects of KISS1 on breast cancer cells both in vivo and in vitro were then identified. Our results indicate that KISS1 can induce apoptosis and inhibit mobility of breast cancer cells. Moreover, the expression of KISS1 in established xenografted tumors was associated with a decrease in tumor size and weight. Accordingly, the survival rate of these mice was significantly higher compared to that of mice bearing tumors that did not express KISS1. We also confirm that KISS1 could decrease the number of circulating tumor cells (CTCs). The plasma levels of metastin and the number of CTCs were significantly positively correlated. Furthermore, we found that KISS1 can inactivate p-MEK and p-ERK. Overall, these studies demonstrate the antitumor activity of KISS1 in the breast cancer cell lines and provide insight into relevant mechanisms that may lead to novel treatments for breast cancer.

View Figures

View References

1.	Salomon JA, Vos T, Hogan DR, et al: Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 380:2129–2143. 2012. View Article : Google Scholar : PubMed/NCBI
2.	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3.	Kushi LH, Byers T, Doyle C, et al: American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 56:254–281; quiz 313–314. 2006. View Article : Google Scholar
4.	Lee JH, Miele ME, Hicks D, et al: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 88:1731–1737. 1996. View Article : Google Scholar : PubMed/NCBI
5.	Makri A, Pissimissis N, Lembessis P, et al: The kisspeptin (KISS-1)/GPR54 system in cancer biology. Cancer Treat Rev. 34:682–692. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Ohtaki T, Shintani Y, Honda S, et al: Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 411:613–617. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Muir AI, Chamberlain L, Elshourbagy NA, et al: AXOR12, a novel human G protein coupled receptor, activated by the peptide KiSS-1. J Biol Chem. 276:28969–28975. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Kotani M, Detheux M, Vandenbogaerde A, et al: The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 276:34631–34636. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Nash KT and Welch DR: The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci. 11:647–659. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Cebrian V, Fierro M, Orenes-Piñero E, et al: KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. Am J Pathol. 179:540–546. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Moya P, Esteban S, Fernandez-Suarez A, et al: KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer. Tumour Biol. 34:471–479. 2013. View Article : Google Scholar : PubMed/NCBI
12.	Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 23:1420–1430. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Osta WA, Chen Y, Mikhitarian K, et al: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64:5818–5824. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Gusterson BA, Ross DT, Heath VJ, et al: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 7:143–148. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar
17.	Pantel K, Brakenhoff RH and Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumor cells. Nat Rev Cancer. 8:329–340. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Masui T, Doi R, Mori T, et al: Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun. 315:85–92. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Martin TA, Watkins G and Jiang WG: KiSS-1 expression in human breast cancer. Clin Exp Metastasis. 22:503–511. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Nicolle G, Comperat E, Nicolaïew N, et al: Metastin (KISS-1) and metastin-coupled receptor (GPR54) expression in transitional cell carcinoma of the bladder. Ann Oncol. 18:605–606. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Zohrabian VM, Nandu H, Gulati N, et al: Gene expression profiling of metastatic brain cancer. Oncol Rep. 18:321–328. 2007.PubMed/NCBI
22.	Hata K, Dhar DK, Watanabe Y, et al: Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer. Eur J Cancer. 43:1452–1459. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Yamashita S, Tsujino Y, Moriguchi K, et al: Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 97:64–71. 2006.PubMed/NCBI
24.	Mooez S, Malik FA, Kayani MA, et al: Expressional alterations and transcript isoforms of metastasis suppressor genes (KAI1 and KiSS1) in breast cancer patients. Asian Pac J Cancer Prev. 12:2785–2791. 2011.PubMed/NCBI
25.	Teng Y, Liu M and Cowell JK: Functional interrelationship between the WASF3 and KISS1 metastasis-associated genes in breast cancer cells. Int J Cancer. 129:2825–2835. 2011. View Article : Google Scholar : PubMed/NCBI
26.	Dhar DK, Naora H, Kubota H, et al: Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. Int J Cancer. 111:868–872. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Zheng S, Chang Y, Hodges KB, et al: Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res. 30:713–718. 2010.PubMed/NCBI
28.	Pantel K and Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer. 4:448–456. 2004. View Article : Google Scholar : PubMed/NCBI
29.	Müller V, Stahmann N, Riethdorf S, et al: Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res. 11:3678–3685. 2005.
30.	Slade MJ, Payne R, Riethdorf S, et al: Comparison of bone marrow, disseminated tumour cells and bloodcirculating tumour cells in breast cancer patients after primary treatment. Br J Cancer. 100:160–166. 2009. View Article : Google Scholar : PubMed/NCBI
31.	Lee YR, Tsunekawa K, Moon MJ, et al: Molecular evolution of multiple forms of kisspeptins and GPR54 receptors in vertebrates. Endocrinology. 150:2837–2846. 2009. View Article : Google Scholar : PubMed/NCBI
32.	Yan C, Wang H and Boyd DD: KISS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha-induced block of p65/p50 nuclear translocation. J Biol Chem. 276:1164–1172. 2001. View Article : Google Scholar : PubMed/NCBI
33.	Mandache E, Gherghiceanu M, Serafinceanu C, et al: Myofibroblast involvement in tubular basement membrane remodeling in type II diabetic nephropathy. Rom J Morphol Embryol. 52:75–79. 2011.PubMed/NCBI
34.	Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
35.	Salomon DS, Brandt R and Ciardiello F: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
36.	Woessmann W, Chen X and Borkhardt A: Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol. 50:397–404. 2002. View Article : Google Scholar : PubMed/NCBI
37.	Bacus SS, Gudkov AV, Lowe M, et al: Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 20:147–155. 2001. View Article : Google Scholar : PubMed/NCBI